161 related articles for article (PubMed ID: 8454225)
1. Probucol as an antioxidant and antiatherogenic drug.
Kuzuya M; Kuzuya F
Free Radic Biol Med; 1993 Jan; 14(1):67-77. PubMed ID: 8454225
[TBL] [Abstract][Full Text] [Related]
2. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.
Carew TE; Schwenke DC; Steinberg D
Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7725-9. PubMed ID: 3478721
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of anti-atherogenic action of probucol].
Ohya T; Egusa G
Nihon Rinsho; 1999 Dec; 57(12):2831-6. PubMed ID: 10638221
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits.
Fruebis J; Steinberg D; Dresel HA; Carew TE
J Clin Invest; 1994 Jul; 94(1):392-8. PubMed ID: 8040279
[TBL] [Abstract][Full Text] [Related]
5. The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881.
Feldman DL; Mogelesky TC; Sharif R; Sawyer WK; Jeune M; Hu CW; Leonards KS; Prescott MF
Atherosclerosis; 1999 Jun; 144(2):343-55. PubMed ID: 10407495
[TBL] [Abstract][Full Text] [Related]
6. Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits.
Lauridsen ST; Mortensen A
Atherosclerosis; 1999 Jan; 142(1):169-78. PubMed ID: 9920518
[TBL] [Abstract][Full Text] [Related]
7. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice.
Bird DA; Tangirala RK; Fruebis J; Steinberg D; Witztum JL; Palinski W
J Lipid Res; 1998 May; 39(5):1079-90. PubMed ID: 9610776
[TBL] [Abstract][Full Text] [Related]
8. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants.
Fruebis J; Bird DA; Pattison J; Palinski W
J Lipid Res; 1997 Dec; 38(12):2455-64. PubMed ID: 9458269
[TBL] [Abstract][Full Text] [Related]
9. The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy.
O'Leary VJ; Tilling L; Fleetwood G; Stone D; Darley-Usmar V
Atherosclerosis; 1996 Jan; 119(2):169-79. PubMed ID: 8808494
[TBL] [Abstract][Full Text] [Related]
10. Role of biologically modified low-density lipoprotein in atherosclerosis.
Carew TE
Am J Cardiol; 1989 Oct; 64(13):18G-22G. PubMed ID: 2679026
[TBL] [Abstract][Full Text] [Related]
11. Probucol protects lipoprotein (a) against oxidative modification.
Naruszewicz M; Selinger E; Dufour R; Davignon J
Metabolism; 1992 Nov; 41(11):1225-8. PubMed ID: 1435295
[TBL] [Abstract][Full Text] [Related]
12. Antiatherogenic effects of the antioxidant BO-653 in three different animal models.
Cynshi O; Kawabe Y; Suzuki T; Takashima Y; Kaise H; Nakamura M; Ohba Y; Kato Y; Tamura K; Hayasaka A; Higashida A; Sakaguchi H; Takeya M; Takahashi K; Inoue K; Noguchi N; Niki E; Kodama T
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10123-8. PubMed ID: 9707611
[TBL] [Abstract][Full Text] [Related]
13. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.
Keaney JF; Xu A; Cunningham D; Jackson T; Frei B; Vita JA
J Clin Invest; 1995 Jun; 95(6):2520-9. PubMed ID: 7769097
[TBL] [Abstract][Full Text] [Related]
14. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
Reaven PD; Parthasarathy S; Beltz WF; Witztum JL
Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191
[TBL] [Abstract][Full Text] [Related]
15. Effect of lipid peroxidation products and antioxidants on the formation of probucol radical in low density lipoproteins.
Shumaev KB; Ruuge EK; Dmitrovsky AA; Bykhovsky VYa ; Kukharchuk VV
Biochemistry (Mosc); 1997 Jun; 62(6):657-60. PubMed ID: 9284547
[TBL] [Abstract][Full Text] [Related]
16. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
17. Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals.
Noguchi N; Gotoh N; Niki E
Biochim Biophys Acta; 1994 Jul; 1213(2):176-82. PubMed ID: 8025128
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
Tamura K; Kato Y; Ishikawa A; Kato Y; Himori M; Yoshida M; Takashima Y; Suzuki T; Kawabe Y; Cynshi O; Kodama T; Niki E; Shimizu M
J Med Chem; 2003 Jul; 46(14):3083-93. PubMed ID: 12825946
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol.
Mao SJ; Yates MT; Parker RA; Chi EM; Jackson RL
Arterioscler Thromb; 1991; 11(5):1266-75. PubMed ID: 1911712
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia.
Dujovne CA; Harris WS; Gerrond LL; Fan J; Muzio F
Am J Cardiol; 1994 Jul; 74(1):38-42. PubMed ID: 8017303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
